Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody
暂无分享，去创建一个
S. Iwata | G. Zalcman | C. Morimoto | T. Taguchi | K. Ohnuma | N. Dang | R. Hatano | Taketo Yamada | N. Isambert | V. Trillet-lenoir | E. Angevin | O. Hosono | J. Alexandre | B. You | Y. Kaneko | Naoto Hirota | F. Valleix | Thomas Podoll | Y. Umezawa | Seiichi Takao | V. Trillet‐Lenoir